← Leaderboards
Nathan Yee
Tambo, Inc.
$1,219,851
Attributed
$2,439,702
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,439,702 · 2
By mechanism
R44$2,139,478 · 1
R43$300,224 · 1
Top collaborators
- Maksim Royzen3 shared
Others in their field
Other Rising Stars on “In Vivo”
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Sabrina Paganoni · Massachusetts General Hospital$17,050,216
- Suma Babu · Massachusetts General Hospital$17,050,216
- Kevin V Grimes · Stanford University$14,783,804
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$12,973,432
Research focus
In VivoLocal TherapyDrug CandidateInjectableCostLeadDesignDoxorubicinAnimal ModelFailureChemistryAdverse Drug EventAnti-Inflammatory AgentsCyclooctenesAntineoplastic AgentsAdverse Drug Experience ReportAqueousDoseBiopolymersAreaAttenuatedDrug DevelopmentAntibioticsMaximum Tolerated Dose
Grant awards (3)
Discovery of solubilizing side chains for in vivo release of diverse drug classes using the Click Activated Protodrugs (CAP) platform$1,209,827
R44 · FY2025 · TR · contact PI
Discovery of solubilizing side chains for in vivo release of diverse drug classes using the Click Activated Protodrugs (CAP) platform$929,651
R44 · FY2024 · TR · contact PI
Generalizable Protodrug Characteristics for In Vivo Drug Release using the Click Activated Protodrugs (CAP) Platform$300,224
R43 · FY2022 · TR · contact PI